Live feed08:35:00·4dPRReleaseAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingAKTX· Akari Therapeutics plcHealth CareOriginal source
